Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Purpose To evaluate the outcomes of patients with chronic ocular inflammatory disease treated with mycophenolate mofetil as an immunosuppressive and steroid-sparing agent.Design Retrospective noncomparative interventional case series.Participants All patients with ocular inflammatory disease treated with mycophenolate mofetil at a single institution between 1998 and 2001.Methods Charts of patients seen on the Ocular Immunology and Uveitis Service at the Massachusetts Eye and Ear Infirmary were reviewed. Patients with chronic ocular inflammatory disease were included in the study.Main outcome measures Control of inflammation, steroid-sparing effect, visual acuity, and adverse reactions were measured.Results A total of 54 patients were evaluated. Control of ocular inflammation with mycophenolate mofetil as monotherapy was achieved in 35 patients (65%) and in 67 eyes (62%), and a steroid-sparing effect was achieved in 29 (54%) patients. Visual acuity was maintained or improved in 51 patients (94%) and in 97 eyes (90%). Side effects requiring discontinuation of medication occurred in 10 patients (18%). There was neither long-term morbidity nor mortality due to mycophenolate mofetil.Conclusions Mycophenolate mofetil is effective in the treatment of patients with steroid-dependent or -resistant chronic ocular inflammatory disorders that fail to respond to conventional steroid treatment. It is a safe and effective steroid-sparing immunomodulatory agent and can be considered an important addition to our armamentarium in the care of patients with ocular inflammatory disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, non-comparative retrospective case series have reported success rates ranging from 37–76% for methotrexate11–13,23 and 54–96% for mycophenolate mofetil.11,14,15,24,25”
From A Bayesian Analysis of a Randomized Clinical Trial Comparing Antimetabolite Therapies for Non-Infectious Uveitis (2017) · cites this paper as [24]
Citations
Cites
Bloch-Michel, E., & Nussenblatt, R. B. (1987) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)74235-7 · Cited by 729
Sarwal, M. M., Yorgin, P. D., Alexander, S., Millan, M. T., Belson, A., Belanger, N., Granucci, L., Major, C., Costaglio, C., Sanchez, J., et al. (2001) · Transplantation · doi:10.1097/00007890-200107150-00006 · Cited by 215
Larkin, G. B., & Lightman, S. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90078-7 · Cited by 152
Ahsan, N., Johnson, C., Gonwa, T., Halloran, P., Stegall, M., Hardy, M., Metzger, R., Shield, C., Rocher, L., Scandling, J., et al. (2001) · Transplantation · doi:10.1097/00007890-200107270-00014 · Cited by 140
Pharmacodynamic Monitoring of Mycophenolate Mofetil
Budde, K., Glander, P., Bauer, S., Braun, K., Waiser, J., Fritsche, L., Mai, I., Roots, I., & Neumayer, H. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.191 · Cited by 71
Chanaud, N. P., Vistica, B. P., Eugui, E. M., Nussenblatt, R. B., ALLISON, A. C., & Gery, I. (1995) · Experimental Eye Research · doi:10.1016/s0014-4835(05)80138-1 · Cited by 70
Treatment of systemic lupus erythematosus with mycophenolate mofetil
Adu, D., Cross, J., & Jayne, D. R. W. (2001) · Lupus · doi:10.1191/096120301673517315 · Cited by 67
Miehsler, W., Reinisch, W., Moser, G., Gangl, A., & Vogelsang, H. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03622.x · Cited by 66
Mycophenolic acid in psoriasis
SPATZ, S., RUDNICKA, A., & McDonald, C. J. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1978.tb06537.x · Cited by 47
New Aspects of the Treatment of Nephrotic Syndrome
Schwarz, A. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v12suppl_1s44 · Cited by 38
Cited by
O'Keefe, G. A. D., & Rao, N. A. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2016.05.002 · Cited by 268
Mycophenolate Mofetil Therapy for Inflammatory Eye Disease
Thorne, J. E., Jabs, D. A., Qazi, F. A., Nguyen, Q. D., Kempen, J. H., & Dunn, J. P. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.020 · Cited by 219
Galor, A., Jabs, D. A., Leder, H. A., Kedhar, S. R., Dunn, J. P., Peters, G. B., & Thorne, J. E. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.04.026 · Cited by 217
Tumour necrosis factor α inhibitors in the treatment of childhood uveitis
Saurenmann, R. K., Levin, A. V., Rose, J. B., Parker, S., Rabinovitch, T., Tyrrell, P. N., Feldman, B. M., Laxer, R. M., Schneider, R., & Silverman, E. D. (2006) · Rheumatology · doi:10.1093/rheumatology/kel030 · Cited by 216
Favorable Response to High-Dose Infliximab for Refractory Childhood Uveitis
Kahn, P., Weiss, M., Imundo, L. F., & Levy, D. M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.01.005 · Cited by 210
Metadata
- Authors
- Baltatzis, S., Tufail, F., Yu, E. N., Vredeveld, C. M., & Foster, C. S.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- ORCID
- Foster, C.Stephen
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2003-05
- Volume
- 110
- Issue
- 5
- Pages
- 1061-1065
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2012806608
- Cited by
- 141
- References
- 12
- Citations by year
- 2024: 5 · 2023: 1 · 2022: 5 · 2021: 1 · 2020: 7 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 10 · 2015: 4 · 2014: 9 · 2013: 5 · 2012: 12
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- mycophenolate mofetil, uveitis, steroid-sparing therapy, immunosuppressive therapy, immunomodulators, visual acuity outcomes, adverse drug reactions
- MeSH terms
- Adolescent, Adult, Chronic Disease, Female, Humans, Immunosuppressive Agents, IMP Dehydrogenase, Inflammation, Male, Middle Aged, Mycophenolic Acid, Endophthalmitis, Retrospective Studies, Visual Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. https://app.cochat.ai/papers/10.1016/s0161-6420(03)00092-7
- The paper
- Baltatzis, S., Tufail, F., Yu, E. N., Vredeveld, C. M., & Foster, C. S. (2003). Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. https://doi.org/10.1016/s0161-6420(03)00092-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.